Digestive Diseases and Sciences

, Volume 56, Issue 8, pp 2349–2353 | Cite as

Association Between Proton Pump Inhibitor Use and Anemia: A Retrospective Cohort Study

  • Erin Sarzynski
  • Chethan Puttarajappa
  • Yan Xie
  • Madhusudan Grover
  • Heather Laird-Fick
Original Article

Abstract

Background

Proton pump inhibitors (PPIs) are widely prescribed to treat gastrointestinal diseases. However, concerns have been raised regarding their long-term use. Gastric acid suppression may decrease iron absorption, and it remains uncertain whether iron-deficiency anemia may result from chronic PPI therapy.

Aims

We aimed to explore the association between chronic PPI use and iron-deficiency anemia.

Methods

We conducted a retrospective cohort study of adult patients in an academic outpatient setting who received PPI therapy for at least 1 year between January 1, 2004 and January 1, 2006. We compared the change in hematologic indices among patients receiving PPI therapy for at least 1 year with matched controls.

Results

Of the 98 patients on chronic PPI therapy who met inclusion criteria, 35% had no documented indication for such therapy. At baseline, demographics and hematologic indices were similar between PPI-users and controls. Among patients on PPI therapy, all hematologic indices decreased from baseline, including hemoglobin (−0.19 g/dL, P = 0.03), hematocrit (−0.63%, P = 0.02), and mean corpuscular volume (−0.49 fL, P = 0.05). PPI users had significant decreases in mean hemoglobin and hematocrit (P < 0.01 for both) compared with matched controls. After adjustment for confounders, including rates of esophagogastroduodenoscopy, colonoscopy and remote cancer status, the odds ratio of decreasing hemoglobin by 1.0 g/dL while on chronic PPI therapy was 5.03 (95% CI, 1.71–14.78, P < 0.01), while the odds ratio of decreasing hematocrit by 3% was 5.46 (95% CI, 1.67–17.85, P < 0.01).

Conclusions

Among adult patients receiving chronic PPI therapy, there is a significant decrease in hematologic indices from baseline.

Keywords

Proton pump inhibitor Anemia Malabsorption Iron deficiency 

References

  1. 1.
    IMS Health Report. 2009 top therapeutic classes by US dispensed prescriptions. Available at: http://www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/Top_Line_Data/Top%20Therapy%20Classes%20by%20U.S.RXs.pdf. Accessed 9 June 2010.
  2. 2.
    IMS Health Report. 2009 top therapeutic classes by US sales. Available at: http://www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/Top_Line_Data/Top%20Therapy%20Classes%20by%20U.S.Sales.pdf. Accessed 9 June 2010.
  3. 3.
    Heidelbaugh J, Goldberg K, Inadomi J. Overutilization of proton pump inhibitors: A review of cost-effectiveness and risk in ppi. Am J Gastroenterol. 2009;104:S27–S32.PubMedCrossRefGoogle Scholar
  4. 4.
    Pham C, Regal R, Bostwick T, Knauf K. Acid suppressive therapy use on an inpatient internal medicine service. Ann Pharmacotherapy. 2006;40:1261–1266.CrossRefGoogle Scholar
  5. 5.
    Ho P, Maddox T, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301:937–944.PubMedCrossRefGoogle Scholar
  6. 6.
    Yang Y, Lewis J, Epstein S, Metz D. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947–2953.PubMedCrossRefGoogle Scholar
  7. 7.
    Gulmez S, Holm A, Frederiksen H, Jensen T, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: A population-based case-control study. Arch Intern Med. 2007;167:950–955.PubMedCrossRefGoogle Scholar
  8. 8.
    FDA drug safety communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors, 2010. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213206.htm. Accessed May 25, 2010.
  9. 9.
    Koop H. Review article: metabolic consequences of long-term inhibition of acid secretion by omeprazole. Aliment Pharmacol Ther. 1992;6:399–406.Google Scholar
  10. 10.
    Marcuard S, Albernaz L, Khazanie P. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin b12). Ann Intern Med. 1994;120:211–215.PubMedGoogle Scholar
  11. 11.
    Bezwoda W, Charlton R, Bothwell T, et al. The importance of gastric hydrochloric acid in the absorption of nonheme food iron. J Clin Gastroenterol. 2000;30:29–33.CrossRefGoogle Scholar
  12. 12.
    Cook J, Brown G, Valberg L. The effect of achylia gastric on iron absorption. J Clin Invest. 1964;43:1185–1191.PubMedCrossRefGoogle Scholar
  13. 13.
    Hines J, Hoffbrand A, Mollin D. The hematologic complications following partial gastrectomy. Am J Med. 1967;43:555–569.PubMedCrossRefGoogle Scholar
  14. 14.
    Wheldon E, Venables C, Johnston I. Late metabolic sequelae of vagotomy and gastroenterostomy. Lancet. 1970;i:437–440.Google Scholar
  15. 15.
    Koop H, Bachem M. Serum iron, ferritin, and vitamin b12 during prolonged omeprazole therapy. J Clin Gastroenterol. 1992;14:288–292.PubMedCrossRefGoogle Scholar
  16. 16.
    Stewart C, Termanini B, Sutliff V, et al. Iron absorption in patient with zollinger-ellison syndrome treated with long-term gastric antisecretory therapy. Aliment Pharmacol Ther. 1998;12:83–98.PubMedCrossRefGoogle Scholar
  17. 17.
    Hutchinson C, Geissler C, Powell J, Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut. 2007;56:1291–1295.PubMedCrossRefGoogle Scholar
  18. 18.
    Sharma V, Brannon M, Carloss E. Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia. South Med J. 2004;97:887–889.PubMedCrossRefGoogle Scholar
  19. 19.
    Schade S, Cohen R, Conrad M. Effect of hydrochloric acid on iron absorption. N Eng J Med. 1968;279:672–674.CrossRefGoogle Scholar
  20. 20.
    Ali T, Roberts D, Tierney W. Long-term safety concerns with proton pump inhibitors. Am J Med. 2009;122:896–903.PubMedCrossRefGoogle Scholar
  21. 21.
    Nealis T, Howden C. Is there a dark side to long-term proton pump inhibitor therapy? Am J Therapeutics. 2008;15:536–542.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Erin Sarzynski
    • 1
  • Chethan Puttarajappa
    • 2
  • Yan Xie
    • 3
  • Madhusudan Grover
    • 4
  • Heather Laird-Fick
    • 1
  1. 1.Department of MedicineMichigan State UniversityEast LansingUSA
  2. 2.Department of Medicine, Renal-Electrolyte DivisionUniversity of PittsburghPittsburghUSA
  3. 3.Center for Statistical Training and ConsultingMichigan State UniversityEast LansingUSA
  4. 4.Division of Gastroenterology and HepatologyMayo ClinicRochesterUSA

Personalised recommendations